500259 Stock Overview
A pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Lyka Labs Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹146.15 |
| 52 Week High | ₹172.65 |
| 52 Week Low | ₹99.95 |
| Beta | 1.11 |
| 11 Month Change | 9.07% |
| 3 Month Change | -2.08% |
| 1 Year Change | 3.73% |
| 33 Year Change | -6.85% |
| 5 Year Change | 793.88% |
| Change since IPO | 573.50% |
Recent News & Updates
Recent updates
Shareholder Returns
| 500259 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.3% | 0.5% | 0.5% |
| 1Y | 3.7% | 42.5% | 27.5% |
Return vs Industry: 500259 underperformed the Indian Pharmaceuticals industry which returned 42.5% over the past year.
Return vs Market: 500259 underperformed the Indian Market which returned 27.5% over the past year.
Price Volatility
| 500259 volatility | |
|---|---|
| 500259 Average Weekly Movement | 7.6% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 500259's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 500259's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1976 | 423 | Kunal Gandhi | www.lykalabs.com |
Lyka Labs Limited, a pharmaceutical company, develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across various therapeutic segments in India. The company manufactures and sells various formulations, including emollient, topical steroid, antifungal agent, topical anti-bacterial, acne management, dermatological formulation, pain killer, anti-aging, cleansing lotion, hair care, anti-dandruff shampoo, sunscreen, anti-acne, cosmeceutical, anti-oxidant, proton pump inhibitor, nutraceuticals, anti-malarial, anti-bacterial, corticosteroid hormones, cephalosporin, dry powder injection, bone resorption inhibitor, anti-oxidant/liver disease, antibiotic, and lyophilized products. It also offers contracted manufacturing services to various large pharmaceutical companies; and medical and technical assistance in the areas of manufacturing know how and manufacturing facilities, as well as technical data, such as molecule stability testing data, impurity profile, and BA/BE clinical study data.
Lyka Labs Limited Fundamentals Summary
| 500259 fundamental statistics | |
|---|---|
| Market cap | ₹5.23b |
| Earnings (TTM) | ₹32.76m |
| Revenue (TTM) | ₹1.27b |
159.8x
P/E Ratio4.1x
P/S RatioIs 500259 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 500259 income statement (TTM) | |
|---|---|
| Revenue | ₹1.27b |
| Cost of Revenue | ₹547.26m |
| Gross Profit | ₹718.63m |
| Other Expenses | ₹685.87m |
| Earnings | ₹32.76m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.92 |
| Gross Margin | 56.77% |
| Net Profit Margin | 2.59% |
| Debt/Equity Ratio | 33.9% |
How did 500259 perform over the long term?
See historical performance and comparison